ARWRARROWHEAD PHARMACEUTICALS, INC.vs its industry peers
A metric-by-metric comparison of ARROWHEAD PHARMACEUTICALS, INC. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARWRThis | $9.5B#3 | — | 20.4x#6 | 11.5x#1 | 23258.2%#1 | 99.7%#1 | 11.9%#1 | -0.4%#1 | — | — | — | — |
| MRNA | $62.1B#1 | — | 9.2x#3 | 32.0x#2 | -39.9%#3 | 20.8%#3 | -158.1%#2 | -41.7%#4 | -54.6%#2 | — | 510.5%#2 | — |
| VKTX | $3.4B#6 | — | 8.3x#2 | — | — | -227.1%#6 | — | -88.1%#6 | — | — | 11.9%#4 | — |
| ERAS | $5.3B#5 | — | 14.6x#4 | — | — | 23.0%#2 | — | -34.4%#3 | — | — | 707.0%#1 | — |
| RVMD | $41.3B#2 | — | 15.9x#5 | — | — | -88.5%#5 | — | -43.4%#5 | — | — | 326.1%#3 | — |
| CGON | $6.5B#4 | — | 6.3x#1 | 1616.7x#3 | 254.7%#2 | -82.9%#4 | -4722.1%#3 | -15.6%#2 | -18.8%#1 | — | — | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice